These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 386306)

  • 1. Sodium valproate: dose-plasma level relationships and interdose fluctuations.
    Vajda FJ; Mihaly GW; Miles JL; Morris PM; Bladin PF
    Clin Exp Neurol; 1978; 15():145-53. PubMed ID: 386306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma sodium valproate levels and clinical response in epilepsy.
    Anthony M; Hinterberger H; Lance JW
    Clin Exp Neurol; 1977; 14():208-15. PubMed ID: 358186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of age, body weight and dose on sodium valproate plasma concentrations in children with epilepsy].
    Jiang Z; Zhang J; Liao HM; Tang JW; Peng QL
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):325-8. PubMed ID: 18554460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels.
    Klotz U; Schweizer C
    Int J Clin Pharmacol Ther Toxicol; 1980 Oct; 18(10):461-5. PubMed ID: 6782028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood level profile of valproate administration under therapeutic conditions in children].
    Meyer FP; Sauer I; Staemmler U; Walther H
    Padiatr Grenzgeb; 1990; 29(4):325-30. PubMed ID: 2216528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Valproate sustained release in the treatment of epilepsy].
    Stefan H; Fraunberger B
    Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium valproate (Epilim) in the treatment of refractory epilepsy.
    Lines DR
    N Z Med J; 1978 Jan; 87(603):9-12. PubMed ID: 347342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state valproate pharmacokinetics during long term therapy.
    Eadie MJ; Heazlewood V; McKauge L; Tyrer JH
    Clin Exp Neurol; 1983; 19():183-91. PubMed ID: 6439443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate].
    Hernández-Fustes OJ; Marcourakis T; de Bittencourt PR
    Rev Neurol; 1999 Jun 1-15; 28(11):1043-7. PubMed ID: 10390769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.
    Miljković B; Pokrajac M; Varagić V; Lević Z
    Int J Clin Pharmacol Res; 1991; 11(3):137-41. PubMed ID: 1809700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some aspects of the clinical use of clonazepam in refractory epilepsy.
    Lander CM; Donnan GA; Bladin PF; Vajda FJ
    Clin Exp Neurol; 1979; 16():325-32. PubMed ID: 121707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Appropriate dosage for maintaining effective serum level at night after taking one dose of magnesium valproate with separate measurements of serum Mg++ concentration].
    Yan CS
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Feb; 24(1):18-20, 61. PubMed ID: 1868760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Certain aspects of interaction between sodium valproate and other anticonvulsant drugs in the therapy of epilepsy in children.
    Sobaniec W
    Mater Med Pol; 1992; 24(2):115-9. PubMed ID: 1307765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of valproate during maintenance therapy in epileptic children.
    Lundberg B; Nergårdh A; Boréus LO
    J Neurol; 1982; 228(2):133-41. PubMed ID: 6185649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.
    Bondareva IB; Jelliffe RW; Sokolov AV; Tischenkova IF
    J Clin Pharm Ther; 2004 Apr; 29(2):105-20. PubMed ID: 15068399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.
    Otoom S; Bakhiet M; Khan A; Sequeira R
    Neuro Endocrinol Lett; 2006; 27(1-2):85-8. PubMed ID: 16648782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of antiepileptic drugs.
    Shakya G; Malla S; Shakya KN; Shrestha R
    JNMA J Nepal Med Assoc; 2008; 47(171):94-7. PubMed ID: 19079370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of di-no-propylacetate and clonazepam in epileptic patients.
    Baruzzi A; Bordo B; Bossi L; Castelli D; Gerna M; Tognoni G; Zagnoni P
    Int J Clin Pharmacol Biopharm; 1977 Sep; 15(9):403-8. PubMed ID: 334679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of sodium valproate: their clinical value.
    Turnbull DM; Rawlins MD; Weightman D; Chadwick DW
    Ann Neurol; 1983 Jul; 14(1):38-42. PubMed ID: 6412620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.